Meningococcemia historical perspective: Difference between revisions

Jump to navigation Jump to search
Line 32: Line 32:


===Epidemics in Africa===
===Epidemics in Africa===
{|style="float:right"
|[[File:Meningococcal belt1.png|thumb|center|500px| <SMALL><SMALL> ''[(http://www.cdc.gov/meningococcal/)]''<ref name="CDC">{{Cite web | title =The Centers for Disease Control and Prevention(CDC) | url = http://www.cdc.gov/meningococcal/}}</ref></SMALL></SMALL>]]
|}
*Epidemics have been happening in Africa for more than 100 years.
*Epidemics have been happening in Africa for more than 100 years.
*The [[disease]] is usually found in Sub Saharan meningitis belt.
*The [[disease]] is usually found in Sub Saharan meningitis belt.
Line 41: Line 44:
*Between 1998 and 2002, African countries within the meningitis belt reported more than 224,000 new cases of [[meningococcal disease]].
*Between 1998 and 2002, African countries within the meningitis belt reported more than 224,000 new cases of [[meningococcal disease]].
*Depicted below is a [[meningococcal]] belt in Africa where historic perspective reports numerous outbreaks.
*Depicted below is a [[meningococcal]] belt in Africa where historic perspective reports numerous outbreaks.
[[File:Meningococcal belt1.png|thumb|center|500px| <SMALL><SMALL> ''[(http://www.cdc.gov/meningococcal/)]''<ref name="CDC">{{Cite web | title =The Centers for Disease Control and Prevention(CDC) | url = http://www.cdc.gov/meningococcal/}}</ref></SMALL></SMALL>]]


===Emergence of Fluoroquinolone-Resistant Meningococcal Disease===
===Emergence of Fluoroquinolone-Resistant Meningococcal Disease===

Revision as of 19:31, 1 December 2014

Meningococcemia Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Meningococcemia from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

History and Symptoms

Physical Examination

Laboratory Findings

Treatment

Medical Therapy

Primary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Meningococcemia historical perspective On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Meningococcemia historical perspective

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Meningococcemia historical perspective

CDC on Meningococcemia historical perspective

Meningococcemia historical perspective in the news

Blogs on Meningococcemia historical perspective

Directions to Hospitals Treating Meningococcemia

Risk calculators and risk factors for Meningococcemia historical perspective

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief: Ammu Susheela, M.D. [2]

Overview

The historical reports indicate that meningococci was first reported in 1805. SInce then for more than 2 hundred years, meningococcus have been causing a high degree of morbidity and mortality. It usually appear as sporadic but reports of outbreak have been reported from different parts of the world especially Sub Saharan African belt. Outbreak usually happens in close communities like schools, colleges and prisons.

Historical Perspective

  • Records indicate that the first case of meningococcal meningitis was described in Geneva in 1805.[1]
  • Another case was reported in New England, New Bedford, Massachusetts in 1806.[2]
  • The causative agent was described as intracellular oval cocci in a cerebrospinal fluid sample by Marchiafava and Celli in 1884.
  • The organism was isolated by Anton Weischselbaum in 1887 and he gave the term diplococcus intracellularis meningitidis.
  • From then on for more than 2 hundred years,meningococcus has caused high rates of morbidity and mortality all around the world.
  • No reports of outbreaks have been reported prior to 1806.
  • The first meningococcal epidemics occurred in early 1900s in sub saharan Africa.

Outbreaks

  • Usually the menigococcalmeningitis cases appear sporadic. Very rarely they can occur as an outbreaks and the outbreaks are usually found in communities like schools, colleges, prisons and such close populations.
  • In temperate regions the number of cases increases in winter and spring. Serogroups B and C together account for a large majority of cases in Europe and America.
  • Several local outbreaks due to Neisseria meningitidis serogroup C have been reported in Canada and the United States (1992-93) and in Spain (1995-97).
  • In 1998 2725 cases were reported in US and 155 cases in Canada.
  • In 1995-1998 in US
  • 33% were due to serotype B
  • 28% due to serotype C
  • 34% due to serotype Y
  • In canada during 1995-98
  • 47% were due to serotype B
  • 40% were due to serotype C
  • 10% due to serotype Y[3]

Epidemics in Africa

[(http://www.cdc.gov/meningococcal/)][4]
  • Epidemics have been happening in Africa for more than 100 years.
  • The disease is usually found in Sub Saharan meningitis belt.
  • Epidemics there occur in the dry season (December to June), ending during the intervening rainy season.
  • Epidemics usually take place in irregular cycles every 5-12 years.
  • 80-85% of all reported case is by Serogroup A meningococci.
  • In 2002 there was a major outbreak of meningococcal disease in Burkina Faso with about 80% of cases due to serogroup W.
  • Between 1988 and 1997, 704,000 cases and more than 100,000 deaths were reported in Africa, some 20,000 occurring in 1996, the largest epidemic year ever recorded.
  • Between 1998 and 2002, African countries within the meningitis belt reported more than 224,000 new cases of meningococcal disease.
  • Depicted below is a meningococcal belt in Africa where historic perspective reports numerous outbreaks.

Emergence of Fluoroquinolone-Resistant Meningococcal Disease

  • Three cases were reported of fluoroquinolone-resistant meningococcal disease in North America. They occurred among residents of the border area of North Dakota and Minnesota during January 2007--January 2008.

References

  1. "Meningococcus".
  2. Stephens DS (2009). "Biology and pathogenesis of the evolutionarily successful, obligate human bacterium Neisseria meningitidis". Vaccine. 27 Suppl 2: B71–7. doi:10.1016/j.vaccine.2009.04.070. PMC 2712446. PMID 19477055.
  3. Pollard AJ, Scheifele D (2001). "Meningococcal disease and vaccination in North America". J Paediatr Child Health. 37 (5): S20–7. PMID 11885732.
  4. "The Centers for Disease Control and Prevention(CDC)".